Why France
Clinical Research
Time in days
Business Processes Enablers
- 1 Regulatory Authority (ANSM) & 1 Central Ethic Committee (CPP)
- Unique agreement template for all hospitals (Fully Executed in 45 days)
- Pilot Phase : in preparation of EU Clinical Trials regulation
- Fast-Track Processes : accelerated authorizations for Investigational Products
- More than 30 years experience for Temporary Authorization for Use (TAU) for innovative not marketed drugs
- EUCROF leader for EU Code of Conduct design with CNIL (French Data Protection Authority) as reference body
- Research Tax Credit = 30% for R&D
Operational excellence
- AFCROs is the largest member of EUCROF with 90 French companies
- Health Data Hub: Unique Public Database about French health data
- Active academic network (F-CRIN) and Public structures (CNCR) to enforce & coordinate Clinical Research
- Fully trained professional by recognized courses; Internationally specialized courses (Pharmaco-epidemiology, Real World Data)
Medical excellence
- Several scientific academic societies
- International reputation of our KOLs
- Large patient advocacy groups led by experts patients
- Oncology & Rare Disease: top French expertise
Oncology
- 45% of French Industrial Trials (versus 25% in Europe)
- 16 labelled centres for cancer early-phase (INCa-CLIP)
- Unique Oncology Network (public or private centers) such as « Centre de Lutte contre le Cancer », Institut Gustave Roussy…
Rare Disease
- 8 out of 24 European Reference Network for addressing patient to specialized centre
- 109 expertise centres for diagnostic and treatment of rare disease+ Public and Private commitment in Rare Diseases research: 3rd French governmental plan for 2018-22
France, an EU leader in healthcare
200B€
Consumption of care and medical goods
8,6%
GDP
200K
Physicians
3 000
Healthcare institutions
400K
Cancer: new patients/year
3M
Inhabitants suffering from rare diseases
150K
Neurology and vascular: stroke/year
227K
Pain management: patients treated/year